- Home
- DTIL vs NRXP Comparison
DTIL vs NRXP Comparison
Compare DTIL & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTIL | NRXP |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.7M | 181.5M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | DTIL | NRXP |
|---|---|---|
| Price | $7.29 | $3.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $45.00 | $38.25 |
| AVG Volume (30 Days) | 632.2K | ★ 784.5K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000,000.00 | N/A |
| Revenue This Year | N/A | $2,547.84 |
| Revenue Next Year | N/A | $1,591.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $1.65 |
| 52 Week High | $9.62 | $5.06 |
Technical Indicators
Market Signals| Indicator | DTIL | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 44.81 |
| Support Level | $6.30 | $2.90 |
| Resistance Level | $7.96 | $4.20 |
| Average True Range (ATR) | 0.62 | 0.32 |
| MACD | -0.19 | -0.03 |
| Stochastic Oscillator | 11.37 | 0.95 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.